2024-02-06 11:36:00 ET
Summary
- Eli Lilly posts results beat, new diabetes and weight loss drug sales handily topped estimates.
- BP to accelerate stock buybacks through the end of next year; shares jump.
- Check out Oppenheimer’s latest report on buy and sell ideas.
Listen below or on the go on Apple Podcasts and Spotify
Our top story so far
Eli Lilly's Mounjaro and Wegovy easily beat sales forecasts. (0:16) DuPont boosts its dividend and launches buyback. (1:37) NYCB's head of risk left before it announced shock results. (2:38)...
Read the full article on Seeking Alpha
For further details see:
Wall Street Lunch: Lilly's Weight-Loss Drugs Drive Results